Compare TTI & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TTI | AGIO |
|---|---|---|
| Founded | 1981 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 1990 | 2013 |
| Metric | TTI | AGIO |
|---|---|---|
| Price | $11.38 | $27.41 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 8 |
| Target Price | $10.40 | ★ $36.25 |
| AVG Volume (30 Days) | ★ 2.2M | 943.3K |
| Earning Date | 02-24-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7085.43 | N/A |
| EPS | ★ 0.92 | N/A |
| Revenue | ★ $618,755,000.00 | $44,791,000.00 |
| Revenue This Year | $5.43 | $27.83 |
| Revenue Next Year | $4.18 | $133.46 |
| P/E Ratio | $12.49 | ★ N/A |
| Revenue Growth | 0.17 | ★ 36.26 |
| 52 Week Low | $2.03 | $22.24 |
| 52 Week High | $12.25 | $46.00 |
| Indicator | TTI | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 60.48 | 45.61 |
| Support Level | $11.11 | $26.25 |
| Resistance Level | $12.10 | $29.93 |
| Average True Range (ATR) | 0.66 | 1.13 |
| MACD | -0.04 | 0.09 |
| Stochastic Oscillator | 60.96 | 31.79 |
Tetra Technologies Inc is a diversified oil and gas services company, focused on completion fluids and associated products and services, water management, frac flowback, production well testing, offshore rig cooling, and compression services. It has two reporting segments namely Completion Fluids & Products, and Water & Flowback Services. The Completion Fluids & Products Division manufactures and markets clear brine fluids, additives, and associated products and services. Majority of revenue is from Completion Fluids & Products. The company derives maximum revenue from United states.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.